Endologix Reports Positive Results from Global ENCORE Analysis with Polymer Endovascular Aneurysm Repair (EVAR) Using Ovation...
March 19 2018 - 4:01PM
Business Wire
Company to Host Investor Conference Call on
March 20, 2018 at 8:30 a.m. ET
Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of
innovative treatments for aortic disorders, today announced the
first results from ENCORE, a pooled, global analysis of several
prospective clinical trials and registries studying polymer
endovascular aneurysm repair (Polymer EVAR) using Ovation®
Abdominal Stent Graft Systems.
ENCORE is a pooled, retrospective analysis of six prospectively
enrolled clinical trials and registries of Ovation Abdominal Stent
Graft Systems encompassing 1,296 patients, 160 centers and 339
investigators in the U.S., Europe and Latin America. This
contemporary analysis standardizes outcome variables across each
study. The data is a mix of real world registry and controlled
data, and all endpoints are presented using Kaplan-Meier survival
estimates.
Median follow up across all studies was 883 days (range 30 days
– 5 years). At five years, the ENCORE analysis included the
following results for Ovation based on the available data:
- 99.1% freedom from AAA-related
mortality
- 99.0% freedom from reintervention for
Type 1a endoleak
- 99.7% freedom from rupture
- 99.2% freedom from conversion
- 96.4% freedom from all device-related
reintervention
“With ENCORE, our objective was to conduct a rigorous, global
evaluation of the available Polymer EVAR clinical data, which
includes nearly 1,300 patients, and to share the consolidated
results with physicians worldwide,” said Matt Thompson, M.D., Chief
Medical Officer for Endologix. “We look forward to sharing
additional analyses from the ENCORE data set in the future, and
we’d like to thank all of the clinical investigators who
participated in the underlying studies that are the basis for the
ENCORE analysis.”
Conference Call
The Company will host a conference call at 8:30 a.m. ET on
Tuesday, March 20, 2018 to discuss the information contained in
this press release and answer questions related to the ENCORE
analysis. To participate in the conference call, dial 888-394-8218
(domestic) or 323-794-2149 (international).
The conference call will also be webcast and can be accessed
from the "Investors" section of the Company's website
at www.endologix.com. The webcast replay of the call will be
available at the same site, approximately one hour after the end of
the call.
A recording of the call will also be available from 11:30 a.m.
ET on Tuesday, March 20, 2018, until 11:59 p.m. ET on Tuesday,
March 27, 2018. To hear this recording, dial 844-512-2921
(domestic) or 412-317-6671 (international) and enter the passcode
2955995.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive
treatments for aortic disorders. The Company's focus is
endovascular stent grafts for the treatment of abdominal aortic
aneurysms (AAA). AAA is a weakening of the wall of the aorta, the
largest artery in the body, resulting in a balloon-like
enlargement. Once AAA develops, it continues to enlarge and, if
left untreated, becomes increasingly susceptible to rupture. The
overall patient mortality rate for ruptured AAA is approximately
80%, making it a leading cause of death in the United States. For
more information, visit www.endologix.com.
Cautions Regarding Forward-Looking Statements
Except for historical information contained herein, this press
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements generally can be identified by the use
of words such as “anticipate,” “expect,” “could,” “may,” “will,”
“believe,” “estimate,” “forecast,” “goal,” “project,” "continue,"
"outlook," “guidance,” "future,” other words of similar meaning and
the use of future dates. Forward-looking statements used in this
press release include, but are not limited to, statements regarding
the ENCORE analysis and presentation of further results, the
accuracy of which are necessarily subject to risks and
uncertainties that may cause future events to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ materially and adversely include Endologix’s ability to
continue to follow-up on patients in the ENCORE analysis and to
provide further ENCORE analyses. Undue reliance should not be
placed upon the forward-looking statements contained in this press
release, which speak only as of the date of this press release.
Endologix undertakes no obligation to update any forward-looking
statements contained in this press release to reflect new
information, events or circumstances after the date they are made,
or to reflect the occurrence of unanticipated events. Please refer
to Endologix's filings with the Securities and Exchange Commission
including its Annual Report on Form 10-K for the year ended
December 31, 2016 and subsequent Quarterly Reports on Form 10-Q,
for more detailed information regarding these risks and
uncertainties and other factors that may cause actual results to
differ materially from those expressed or implied.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180319006190/en/
Investors:Endologix, Inc.Vaseem Mahboob, CFO,
949-595-7200
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Apr 2023 to Apr 2024